9966 (9966) Fair Value & Analysis
Healthcare · Market cap HK$7.1B
Fair value as of: Jul 3, 2026
From 1 valuation models · updated today
Share price −10.5% over the past month.
Price vs Fair Value (12 months)
12‑month range HK$6.10 – HK$15.33 · fair‑value band HK$0.7800 – HK$1.48 · the HK$7.30 price screens above the HK$1.19 fair value. As of Jul 3, 2026.
✦ Which stocks are undervalued right now? Check free Discover now →Analysis
9966 (9966) currently trades at HK$7.30, while our model-based Fair Value estimate is HK$1.19 — implying the stock looks roughly 83.7% overvalued today. We read business quality at 46/100 (below-average quality), in the Healthcare sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium — the entry price still matters most (evidence: low).
Over the trailing twelve months, 9966 generated revenue of HK$566M at a net margin of -20.1%. Revenue declined 47.1% year over year. It earns a return on equity of -6.4%. The balance sheet holds a net cash position of HK$136M. Fundamentals as of Jul 3, 2026
Key figures & financial health
More key figures
Figures from reported company fundamentals (EODHD) · as of Jul 3, 2026. TTM = trailing twelve months.
Revenue & earnings trend
FY2021 – FY2025 · reported fiscal years
9966 reported revenue of HK$552M in FY2025 versus HK$146M in FY2021, a compound +39.4%/yr. Reported net income was −HK$111M in FY2025.
Is 9966 fairly valued? → Check now
Similar stocks
6 more Biotechnology stocks, each showing price versus our Fair Value estimate (as of Jul 3, 2026).
| Stock | Price | Fair Value | vs Fair Value |
|---|---|---|---|
| Vertex Pharmaceuticals Incorporated VRTX | 7,746 MXN | 449.62 MXN | -94% |
| Regeneron Pharmaceuticals, Inc REGN | $601.65 | $577.20 | -4% |
| UCB SA UCB | €251.70 | €180.06 | -28% |
| argenx SE ARGNF | $900.00 | $382.64 | -57% |
| Alnylam Pharmaceuticals, Inc ALNY | $288.18 | $51.70 | -82% |
| Samsung Biologics Co 207940 | 1,000,000 KRW | 724,332 KRW | -28% |
Explore undervalued stocks
More undervalued Healthcare stocks →
Frequently asked questions
Is 9966 (9966) undervalued?
What is the fair value of 9966?
What is the quality score of 9966?
What is the revenue of 9966 (9966)?
What is the net profit margin of 9966?
How we calculate Fair Value
Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.
Educational research only · not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.